Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.

5596Background: Lenvatinib (LEN) is an inhibitor of VEGFR 1−3, FGFR 1−4, and other kinases. Pembrolizumab (PEM) is an anti-PD-1 antibody. We report updated interim results from a phase 1b/2 study e...